Saxenda & Victoza (Liraglutide) and Erectile Dysfunction: The Evidence

Obesity and type 2 diabetes are two of the strongest modifiable causes of erectile dysfunction, and they work through the same lesion: endothelial dysfunction. The penis is a vascular organ, and when obesity-driven insulin resistance, inflammation, and low testosterone damage the cavernosal endothelium, erections fail. The good news is that this lesion is largely reversible with weight loss — the landmark Esposito 2004 JAMA trial^[1] restored erectile function in roughly a third of obese men with ED through diet and exercise alone. Where does liraglutide fit? It is the older, once-daily GLP-1 — Saxenda 3.0 mg for weight, Victoza up to 1.8 mg for diabetes — and it produces less weight loss than the newer drugs: about 8% in the SCALE Obesity and Prediabetes trial^[12], versus ~15% for semaglutide^[10] and ~21% for tirzepatide^[11]. That puts liraglutide's weight loss in the same ballpark as the Esposito lifestyle intervention — enough to expect a real but modest ED benefit — with a small bonus: liraglutide is the one GLP-1 with its own direct, positive erectile-function data in hypogonadal men. This article walks through the mechanism, the evidence, and the honest trade-offs. For the desire side, see our liraglutide and libido companion.

The honest summary

• Obesity and diabetes are leading modifiable causes of ED. The Massachusetts Male Aging Study (Feldman 1994^[9]) established the prevalence and put diabetes, hypertension, and cardiovascular disease at the top of the medical-correlates list. Obesity sits alongside them.
• The mechanism is mostly vascular. Endothelial dysfunction from obesity- and diabetes-driven insulin resistance, chronic inflammation, and adipose-tissue aromatization of testosterone to estradiol all converge on the cavernosal endothelium.
• ED is largely reversible with weight loss. Esposito 2004 JAMA^[1] restored erectile function in ~31% of obese men with a 2-year Mediterranean-diet-plus-exercise program (~15 kg lost) versus ~5% of controls; the Mediterranean pattern itself correlates with better erectile function (Giugliano 2006^[2], Giugliano 2010^[3]).
• Bariatric surgery improves ED in roughly half of patients (Glina 2017 systematic review^[6]) — the largest weight loss, the largest effect.
• Liraglutide is the smaller-weight-loss GLP-1. SCALE Obesity showed about −8% on liraglutide 3.0 mg^[12], versus −14.9% for semaglutide^[10] and −20.9% for tirzepatide^[11]. That is close to the Esposito lifestyle magnitude, so a real but modest ED benefit is reasonable to expect.
• Liraglutide has a small direct, positive ED signal. Unlike semaglutide and tirzepatide, liraglutide has published data adding it in obese hypogonadal men, with improved erectile function — a bonus for the honest evidence base, though still small studies.
• Low testosterone from obesity often improves with weight loss. The EMAS longitudinal data (Camacho 2013^[7]) and Grossmann 2020^[8] show obesity-associated functional hypogonadism is often reversible with sustained weight loss.
• Weight loss does not fix structural ED. Post-prostatectomy, Peyronie's, neurogenic, severe venous-leak, and medication-induced ED need separate evaluation. Urology referral is the right move.

Why obesity and diabetes cause ED in the first place

Erection is a vascular event. Sexual stimulation triggers parasympathetic release of nitric oxide from cavernosal nerve endings and endothelium; nitric oxide raises cyclic GMP in vascular smooth muscle; the muscle relaxes; the cavernosal sinusoids fill with arterial blood; venous outflow is compressed; the penis becomes erect. Every step depends on a healthy vascular endothelium and adequate testosterone. Obesity and diabetes — the two conditions liraglutide treats — damage that chain in three converging ways:

1. Endothelial dysfunction. Insulin resistance and chronic low-grade inflammation reduce endothelial nitric oxide bioavailability — the same mechanism that drives early atherosclerosis. The penile arteries are roughly 1–2 mm in diameter versus 3–4 mm for the coronaries, so vascular ED often precedes a coronary event by 3–5 years and is recognized as an early warning sign for occult coronary artery disease.
2. Low testosterone (obesity-associated hypogonadism). Adipose tissue expresses aromatase, converting testosterone to estradiol, and obesity suppresses hypothalamic GnRH pulses. The result is measurably lower total and free testosterone (Grossmann 2020^[8]). The EMAS cohort (Camacho 2013^[7]) showed weight gain accelerates the testosterone decline and weight loss can reverse it.
3. Co-occurring vascular disease. Type 2 diabetes, hypertension, dyslipidemia, and sleep apnea cluster with obesity and independently damage the endothelium. The Feldman MMAS data^[9] placed diabetes and cardiovascular disease at the top of the ED-correlates list.

These are reversible mechanisms, mostly — which is why the weight-loss-and-glycemic intervention works. And it is worth noting that liraglutide, as Victoza, is a diabetes drug: for a man whose ED is driven by both obesity and poorly-controlled diabetes, improving glycemic control is a second lever on the same endothelial lesion, on top of the weight loss.

Esposito 2004 JAMA: the landmark that anchors the whole field

The single most-cited piece of evidence in the weight-loss-and-ED literature is the Esposito 2004 randomized controlled trial^[1]. It enrolled 110 obese men (BMI 36–40) with mild-to-moderate ED and no diabetes, hypertension, or hyperlipidemia, and randomized them to a 2-year Mediterranean-pattern diet plus structured exercise versus general advice. At 2 years the intervention group lost roughly 15 kg versus about 2 kg in controls, mean IIEF-5 scores rose, and approximately 31% of intervention men returned to a non-ED score versus about 5% of controls. Endothelial-function biomarkers moved in the same direction.

Two caveats matter for the liraglutide reader. First, the trial enrolled men without overt cardiometabolic disease — the highest-likelihood-of-response subgroup. Second, the intervention was intensive and sustained; the “30% reversal” figure depends on adherence for 24 months. The dietary pattern itself carries independent weight: adherence to a Mediterranean diet correlates with better erectile function in the general population (Giugliano 2006^[2]) and specifically in men with type 2 diabetes (Giugliano 2010^[3]). The mechanistic follow-ups by Khoo established the same effect from exercise alone (Khoo 2013^[4]) and from meal-replacement caloric restriction (Khoo 2014^[5]), both improving IIEF-5, endothelial function, and testosterone.

Where liraglutide fits: the magnitude question

As of 2026 there is no published randomized controlled trial of liraglutide with erectile function as a primary or pre-specified secondary endpoint. But liraglutide is in an unusually favorable position for inference, for two reasons.

First, the weight-loss magnitude sits right on top of the Esposito evidence. The pivotal SCALE Obesity and Prediabetes trial (Pi-Sunyer 2015, NEJM^[12]) randomized adults with obesity or overweight-with-comorbidity to liraglutide 3.0 mg or placebo and reported roughly 8% body-weight loss at 56 weeks. In absolute terms for a man of ~100 kg, that is close to the ~15 kg lost in the Esposito intervention that restored ED in a third of participants. So the directional expectation for an obese man with vascular-pattern ED who loses ~8% on Saxenda is a real, if modest, improvement in erectile function — smaller than what he could expect on semaglutide (STEP-1 −14.9%^[10]) or tirzepatide (SURMOUNT-1 −20.9%^[11]), and well below the ~50% ED-improvement seen after bariatric surgery (Glina 2017^[6]).

Second, liraglutide is the one GLP-1 with a direct, positive erectile signal. Small studies added liraglutide in obese men with functional hypogonadism and reported improved erectile function and sexual outcomes — consistent with the weight-loss-raises-testosterone chain (EMAS, Camacho 2013^[7]). These are small, non-randomized-for-ED studies, but they are more than semaglutide or tirzepatide have for erectile function specifically, and they all point up rather than down.

The chart makes the trade-off concrete. Liraglutide's weight loss is the smallest of the pharmacologic options, but it is not trivial — it lands just below the Esposito lifestyle magnitude that produced a measurable ED benefit. The honest framing: liraglutide is a reasonable ED-adjacent choice for a man who needs its once-daily profile or its diabetes indication (Victoza), while a man whose primary goal is maximal weight-loss-driven ED reversal will get more leverage from a once-weekly higher-potency drug.

The hypogonadism angle: weight loss plus testosterone

Obese men have lower circulating testosterone and higher estradiol than lean peers because of adipose aromatase and suppressed GnRH — “obesity-associated” or “functional” hypogonadism (Grossmann 2020^[8]). The EMAS longitudinal cohort (Camacho 2013^[7]) showed that large sustained weight loss blunts or reverses the age-related testosterone decline, lowering estradiol and raising SHBG. The practical implication for a man with ED and a borderline-low morning testosterone: sustained weight loss — even liraglutide's more modest ~8%^[12] — is one of the few interventions that can move testosterone back toward range without exogenous replacement. This is worth discussing with a urologist or endocrinologist before starting testosterone therapy, because functional hypogonadism in an obese man is often reversible.

PDE5 inhibitors with liraglutide: the interaction question

Men on Saxenda or Victoza frequently ask whether sildenafil (Viagra), tadalafil (Cialis), or vardenafil are safe alongside it. The short answer is yes, with the usual PDE5-inhibitor cautions. Sildenafil, tadalafil, and vardenafil are metabolized primarily by hepatic CYP3A4. Liraglutide is a peptide drug degraded by general protease activity and cleared without meaningful CYP3A4 involvement — it is not a CYP3A4 substrate, inhibitor, or inducer, and no PDE5-inhibitor interaction warning appears on the Saxenda or Victoza prescribing information. The considerations the prescribing clinician will check independently:

• Nitrates are the absolute contraindication. PDE5 inhibitors plus nitrates can cause severe hypotension — independent of GLP-1 status.
• Significant cardiovascular disease. Use PDE5 inhibitors cautiously in men with unstable angina, recent myocardial infarction, or significant hypotension.
• GI-symptom overlap. Both liraglutide and the PDE5 inhibitors can cause mild nausea or dyspepsia; a man already nauseated during liraglutide titration may notice the PDE5-inhibitor component more. A comfort issue, not a safety one.
• Daily-dose tadalafil. The 2.5–5 mg daily tadalafil schedule is often better tolerated than higher on-demand dosing for men with GLP-1-related fullness.

When weight loss is the wrong tool

Erectile dysfunction is not a single disease. Several categories do not respond to weight loss — on liraglutide or anything else — because the lesion is structural or neurological, not vascular:

• Post-radical-prostatectomy ED. Cavernosal nerve injury is structural; weight loss does not regenerate the neurovascular bundles. Treatment is PDE5 inhibitors, intracavernosal injections, vacuum devices, or prosthesis.
• Peyronie's disease. Fibrous tunica plaque causes curvature and erectile difficulty independent of vascular status.
• Spinal cord injury and neurogenic ED. Weight loss does not restore lost autonomic pathways.
• Severe venous-leak ED. A mechanical failure of the veno-occlusive mechanism.
• Medication-induced ED. SSRIs, some beta-blockers, finasteride, and certain antipsychotics can cause ED; address the offending drug with the prescriber first.
• Psychogenic ED. Performance anxiety, depression, and relationship stress are common in younger men with normal vascular status. The tell is that psychogenic ED is situational (morning and masturbatory erections intact), whereas organic ED affects all situations.

For any new ED, the right first step is a primary-care or urology evaluation: morning total testosterone, fasting glucose or HbA1c, lipids, blood pressure, medication review, and sleep-apnea screening. Weight loss on liraglutide can be a parallel intervention even when it is not the primary one. See our weight loss reverses ED and GLP-1 and ED reversal reviews for the full mechanism and evidence.

What we still don't know

• No published liraglutide RCT has used IIEF-5 or any validated ED instrument as a pre-specified endpoint. The case is built on the SCALE weight-loss magnitude^[12], the weight-loss-to-ED chain^[1][6], and small direct signals in hypogonadal men.
• The durability of any ED improvement after stopping liraglutide is unstudied. Weight regain after GLP-1 cessation is well documented; whether ED outcomes regress in parallel is unknown but should be assumed.
• Whether liraglutide's smaller weight loss^[12] translates into a proportionally smaller ED benefit, or whether a threshold of weight loss matters more, has not been quantified.
• The relative contribution of glycemic improvement (the Victoza indication) versus weight loss to endothelial recovery in a diabetic man with ED has not been isolated.

Bottom line

• Obesity and diabetes are leading modifiable causes of ED, working through endothelial dysfunction and obesity-associated low testosterone — both largely reversible with weight loss.
• Esposito 2004 JAMA^[1] restored erectile function in ~31% of obese men through diet and exercise; bariatric surgery improves ED in ~half (Glina 2017^[6]). The weight-loss-to-ED chain is well established.
• Liraglutide is the older, once-daily, smaller-weight-loss GLP-1 — about 8% in SCALE^[12] versus ~15%^[10] and ~21%^[11] for the newer drugs. That lands near the Esposito lifestyle magnitude, so a real but modest ED benefit is reasonable to expect, with more leverage available from higher-potency drugs.
• Liraglutide is the one GLP-1 with a direct, positive erectile signal in hypogonadal men, and low testosterone from obesity often rises with weight loss (EMAS^[7], Grossmann 2020^[8]).
• Sildenafil, tadalafil, and vardenafil have no clinically significant interaction with liraglutide; the absolute PDE5-inhibitor contraindication remains nitrates.
• Weight loss does not fix structural ED — post-prostatectomy, Peyronie's, neurogenic, venous-leak, or medication-induced ED need separate workup. The right first move for new ED is a urology or primary-care evaluation.

Related research

• Liraglutide and libido — the desire-side companion to this article, covering both men and women
• GLP-1s and erectile dysfunction — the full cross-drug weight-loss-and-ED evidence review
• Weight loss reverses ED — the mechanism and RCT evidence for erectile-function recovery
• GLP-1s and ED reversal — how the newer drugs fit the reversal picture
• GLP-1s, testosterone, and male fertility — how weight loss moves testosterone in men
• GLP-1s and libido: the cross-drug hub — the master overview spanning men and women

Important disclaimer. This article is educational and does not constitute medical advice. New or worsening erectile dysfunction warrants evaluation by a primary-care clinician or urologist, including a morning total testosterone, fasting glucose or HbA1c, lipid panel, blood-pressure assessment, medication review, and sleep-apnea screening. ED can be an early warning sign of occult coronary artery disease. Sildenafil, tadalafil, and vardenafil are contraindicated in men taking any form of nitrate. Do not start, stop, or change any prescription medication based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-06-30.

Last verified: 2026-06-30. Next review: every 12 months, or sooner if a randomized liraglutide trial with a pre-specified erectile-function endpoint is published.